First-line (1L) osimertinib plus platinum-pemetrexed in EGFRmutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results

被引：0
|
作者：
Planchard, D. [1 ]
Poltoratskiy, A. [2 ]
Kim, S-W. [3 ]
Kim, T. M. [4 ]
Yanagitani, N. [5 ]
Kagamu, H. [6 ]
Feng, P-H. [7 ]
Hughes, B. [8 ]
Yang, T-Y. [9 ]
Yang, J. C-H. [10 ,11 ]
Lee, C. K. [12 ]
Karaseva, N. [13 ]
Mitchell, P. [14 ]
Tambo, Y. [15 ]
Monterroso, E. Armenteros [16 ]
Todd, A. [17 ]
Sahasrabudhe, A. [18 ]
Janne, P. A. [19 ]
Kobayashi, K. [20 ]
机构：
[1] Inst Gustave Roussy, Dept Med Oncol, Thorac Unit, Villejuif, France
[2] Petrov Res Inst Oncol, Dept Preclin & Clin Trials, St Petersburg, Russia
[3] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[4] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[5] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Med Oncol, Tokyo, Japan
[6] Saitama Med Univ, Dept Gen Surg, Saitama, Japan
[7] Taipei Med Univ, Shuang Ho Hosp, Div Pulm Med, Dept Internal Med, Taipei, Taiwan
[8] Prince Charles Hosp, Dept Canc Care Serv, Herston, Qld, Australia
[9] Taichung Vet Gen Hosp, Dept Pulm Med, Taichung, Taiwan
[10] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[11] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[12] St George Hosp, Dept Med Oncol, Canc Care Ctr, Kogarah, NSW, Australia
[13] City Clin Oncol Hosp, Thorac Dept, St Petersburg, Russia
[14] Austin Hlth, Olivia Newton John Canc Ctr, Dept Oncol, Melbourne, Vic, Australia
[15] Kanazawa Univ Hosp, Dept Resp Med, Kanazawa, Ishikawa, Japan
[16] AstraZeneca, Late Dev Oncol R&D, Cambridge, England
[17] AstraZeneca, Oncol Biometr, Cambridge, England
[18] AstraZeneca, Dept Patient Safety Oncol, Cambridge, England
[19] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Dept Med Oncol, Boston, MA 02115 USA
[20] Saitama Med Univ, Int Med Ctr, Dept Resp Med, Hidaka, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.646
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
568P
引用
收藏
页码：S1692 / S1693
页数：2
相关论文
共 50 条
  • [31] CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC
    Hellmann, Matthew David
    Gettinger, Scott N.
    Goldman, Jonathan Wade
    Brahmer, Julie R.
    Borghaei, Hossein
    Chow, Laura Q.
    Ready, Neal
    Gerber, David E.
    Juergens, Rosalyn A.
    Shepherd, Frances A.
    Laurie, Scott Andrew
    Zhou, Ye
    Geese, William J.
    Agrawal, Shruti
    Li, Xuemei
    Antonia, Scott Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO plus RELA) versus NIVO plus ipilimumab (NIVO plus IPI) in advanced melanoma: An updated indirect treatment comparison (ITC)
    Schadendorf, Dirk
    Tawbi, Hussein A.
    Lipson, Evan J.
    Hodi, F. Stephen
    Ascierto, Paolo Antonio
    Larkin, James
    Lao, Christopher D.
    Grob, Jean-Jacques
    Ejzykowicz, Flavia
    Palaia, Jennell
    Horton, Viviana Garcia
    Zhou, Zheng-Yi
    Christensen, Dana
    Rosenblatt, Lisa
    McDonald, Laura
    Ratto, Barbara
    Salvatore, Anthony
    Patel, Divya
    Sakkal, Leon A.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study
    Yang, Yunpeng
    Sun, Jiya
    Wang, Zhehai
    Fang, Jian
    Yu, Qitao
    Han, Baohui
    Cang, Shundong
    Chen, Gongyan
    Mei, Xiaodong
    Yang, Zhixiong
    Ma, Rui
    Bi, Minghong
    Ren, Xiubao
    Zhou, Jianying
    Li, Baolan
    Song, Yong
    Feng, Jifeng
    Li, Juan
    He, Zhiyong
    Zhou, Rui
    Li, Weimin
    Lu, You
    Zhou, Hui
    Wang, Shuyan
    Sun, Luyao
    Puig, Oscar
    Mancao, Christoph
    Peng, Bo
    Fang, Wenfeng
    Xu, Wei
    Zhang, Li
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 2109 - 2120
  • [34] Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1-Selected Patients With Advanced NSCLC
    Carcereny, E.
    Felip, E.
    Reck, M.
    Patel, J.
    Heist, R.
    Balmanoukian, A.
    Chow, L.
    Paz-Ares, L.
    Qiu, J.
    Coleman, S.
    Mocci, S.
    Sandler, A.
    Kurata, T.
    Shepherd, F.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1791 - S1792
  • [35] POST-PROGRESSION AND SAFETY OUTCOMES WITH FIRST-LINE (1L) AMIVANTAMAB PLUS LAZERTINIB VERSUS OSIMERTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH COMMON EGFR MUTATIONS: IMPLICATIONS FOR BEST MANAGEMENT PRACTICES
    Smith, Sarah
    Spira, Alexander I.
    Nguyen, Danny
    Sethi, Seema
    Gadgeel, Shirish
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [36] KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLC
    Awad, M. M.
    Gadgeel, S. M.
    Borghaei, H.
    Patnaik, A.
    Yang, J. Chih-Hsin
    Powell, S. F.
    Gentzler, R. D.
    Martins, R. G.
    Stevenson, J. P.
    Altan, M.
    Jalal, S. I.
    Panwalkar, A.
    Gubens, M.
    Sequist, L. V.
    Saraf, S.
    Zhao, B.
    Piperdi, B.
    Langer, C. J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S8 - S8
  • [37] JASPER: Efficacy and safety of first-line (1L) niraparib plus a programmed death receptor 1 inhibitor (PD-1i) in patients with advanced non-small cell lung cancer (NSCLC)
    Ramalingam, S. S.
    Thara, E.
    Rao, S.
    Awad, M. M.
    Dowlati, A.
    Haque, B.
    Veatch, A. L.
    Stinchcombe, T.
    Dy, G. K.
    Spigel, D. R.
    Singh, N. Iyer
    Evilevitch, L.
    Wang, Z.
    Tang, Y.
    Teslenko, I.
    Roychoudhury, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S819 - S820
  • [38] ORCHARD osimertinib plus savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib
    Yu, H. A.
    Ambrose, H.
    Baik, C.
    Cho, B. C.
    Cocco, E.
    Goldberg, S. B.
    Goldman, J. W.
    Kraljevic, S.
    de langen, A. J.
    Okamoto, I.
    Piotrowska, Z.
    Pluta, M.
    Powar, S.
    Aransay, N. Reguart
    Riess, J. W.
    Le, X.
    ANNALS OF ONCOLOGY, 2021, 32 : S978 - S979
  • [39] EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
    Gogishvili, M.
    Melkadze, T.
    Makharadze, T.
    Giorgadze, D.
    Dvorkin, M.
    Penkov, K. D.
    Laktionov, K.
    Nemsadze, G.
    Nechaeva, M.
    Rozhkova, I.
    Kalinka, E.
    Gessner, C.
    Jaime, B. Moreno
    Passalacqua, R.
    Li, S.
    McGuire, K.
    Quek, R. G.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S1567 - S1568
  • [40] EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
    Gogishvili, M.
    Melkadze, T.
    Makharadze, T.
    Giorgadze, D.
    Dvorkin, M.
    Penkov, K. D.
    Laktionov, K.
    Nemsadze, G.
    Nechaeva, M.
    Rozhkova, I.
    Kalinka, E.
    Gessner, C.
    Moreno-Jaime, B.
    Passalacqua, R.
    Li, S.
    McGuire, K.
    Quek, R. G. W.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1328 - S1328
12345